Details for New Drug Application (NDA): 022311
✉ Email this page to a colleague
The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the plerixafor profile page.
Summary for 022311
Tradename: | MOZOBIL |
Applicant: | Genzyme |
Ingredient: | plerixafor |
Patents: | 0 |
Pharmacology for NDA: 022311
Physiological Effect | Increased Hematopoietic Stem Cell Mobilization |
Suppliers and Packaging for NDA: 022311
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311 | NDA | sanofi-aventis U.S. LLC | 0024-5862 | 0024-5862-01 | 1 VIAL, SINGLE-USE in 1 CARTON (0024-5862-01) / 1.2 mL in 1 VIAL, SINGLE-USE |
MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311 | NDA AUTHORIZED GENERIC | Fresenius Kabi Usa, LLC | 65219-284 | 65219-284-12 | 1 VIAL, SINGLE-USE in 1 CARTON (65219-284-12) / 1.2 mL in 1 VIAL, SINGLE-USE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 24MG/1.2ML (20MG/ML) | ||||
Approval Date: | Dec 15, 2008 | TE: | AP | RLD: | Yes |
Expired US Patents for NDA 022311
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription